Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DRRX
2301
DELISTED
DURECT Corp
DRRX
| $2.09M | ﹤0.01% |
320,789
+16,180
| +5% | +$101K |
|
|
ALYA
2302
DELISTED
Alithya Group Inc Class A Subordinate Voting Shares
ALYA
| $2.09M | ﹤0.01% |
798,176
+16,500
| +2% | +$50K |
|
2303
Escalade
ESCA
$288M
| $2.08M | ﹤0.01% |
181,660
| – | – |
|
2304
Textron
TXT
$15B
| $2.08M | ﹤0.01% |
39,300
-578,500
| -94% | -$29.3M |
|
2305
Ohio Valley Banc Corp
OVBC
$198M
| $2.08M | ﹤0.01% |
53,900
-2,766
| -5% | -$104K |
|
|
CTO
2306
CTO Realty Growth
CTO
$820M
| $2.08M | ﹤0.01% |
128,203
+60,417
| +89% | +$989K |
|
2307
Radiant Logistics
RLGT
$388M
| $2.07M | ﹤0.01% |
337,700
-284,900
| -46% | -$1.86M |
|
2308
Fresenius Medical Care
FMS
$13.8B
| $2.07M | ﹤0.01% |
52,600
+24,600
| +88% | +$974K |
|
|
TCFC
2309
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $2.06M | ﹤0.01% |
61,214
+8,701
| +17% | +$266K |
|
|
TTSH
2310
DELISTED
Tile Shop Holdings
TTSH
| $2.06M | ﹤0.01% |
515,600
+95,300
| +23% | +$453K |
|
|
SIOX
2311
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $2.06M | ﹤0.01% |
329,823
+7,435
| +2% | +$56.6K |
|
2312
Nomura Holdings
NMR
$27.9B
| $2.05M | ﹤0.01% |
577,100
+492,700
| +584% | +$1.72M |
|
2313
Vince Holding Corp
VNCE
$80.7M
| $2.05M | ﹤0.01% |
146,747
-1,800
| -1% | -$24.1K |
|
|
FARO
2314
DELISTED
Faro Technologies
FARO
| $2.04M | ﹤0.01% |
38,900
-67,000
| -63% | -$3.39M |
|
2315
Grupo SIMEC
SIM
$4.22B
| $2.04M | ﹤0.01% |
252,195
-305
| -0.1% | -$2.63K |
|
2316
BioLife Solutions
BLFS
$1.55B
| $2.04M | ﹤0.01% |
120,600
-189,300
| -61% | -$3.3M |
|
2317
Lennar Class B
LEN.B
$19.7B
| $2.04M | ﹤0.01% |
55,822
-897
| -2% | -$35.1K |
|
2318
Acadia Realty Trust
AKR
$3.08B
| $2.04M | ﹤0.01% |
74,500
-84,900
| -53% | -$2.38M |
|
|
SEEL
2319
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $2.04M | ﹤0.01% |
242
+118
| +95% | +$1.24M |
|
|
FCCY
2320
DELISTED
1st Constitution Bancorp
FCCY
| $2.03M | ﹤0.01% |
110,100
+6,591
| +6% | +$123K |
|
2321
Protalix BioTherapeutics
PLX
$183M
| $2.03M | ﹤0.01% |
432,653
+30,882
| +8% | +$130K |
|
2322
Vanguard FTSE All-World ex-US ETF
VEU
$66.8B
| $2.03M | ﹤0.01% |
39,800
-28,600
| -42% | -$1.44M |
|
|
CRHM
2323
DELISTED
CRH Medical Corporation
CRHM
| $2.03M | ﹤0.01% |
669,700
+22,500
| +3% | +$64.4K |
|
2324
Varex Imaging
VREX
$467M
| $2.03M | ﹤0.01% |
66,100
+38,800
| +142% | +$1.18M |
|
|
ARQL
2325
DELISTED
Arqule Inc
ARQL
| $2.03M | ﹤0.01% |
+183,983
| New | +$1.28M |
|
Similar funds
Renaissance Technologies's Q2 2019 Portfolio in Review
As of Q2 2019, Renaissance Technologies held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Renaissance Technologies's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Renaissance Technologies's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Renaissance Technologies added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Renaissance Technologies's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Renaissance Technologies fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Renaissance Technologies's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Renaissance Technologies opened 495 new positions and closed 397 in Q2 2019.
- Renaissance Technologies's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.